These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 27935018)

  • 1. Tolerability and efficacy of perampanel in children with refractory epilepsy.
    Heyman E; Lahat E; Levin N; Epstein O; Lazinger M; Berkovitch M; Gandelman-Marton R
    Dev Med Child Neurol; 2017 Apr; 59(4):441-444. PubMed ID: 27935018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study.
    De Liso P; Vigevano F; Specchio N; De Palma L; Bonanni P; Osanni E; Coppola G; Parisi P; Grosso S; Verrotti A; Spalice A; Nicita F; Zamponi N; Siliquini S; Giordano L; Martelli P; Guerrini R; Rosati A; Ilvento L; Belcastro V; Striano P; Vari MS; Capovilla G; Beccaria F; Bruni O; Luchetti A; Gobbi G; Russo A; Pruna D; Tozzi AE; Cusmai R
    Epilepsy Res; 2016 Nov; 127():93-100. PubMed ID: 27568598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: A UK national multicentre study.
    Swiderska N; Tan HJ; Rajai A; Silwal A; Desurkar A; Martland T
    Seizure; 2017 Nov; 52():63-70. PubMed ID: 28992560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
    Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
    Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of perampanel in young children with drug-resistant epilepsy.
    Chang FM; Fan PC; Weng WC; Chang CH; Lee WT
    Seizure; 2020 Feb; 75():82-86. PubMed ID: 31901668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics.
    Lin KL; Lin JJ; Chou ML; Hung PC; Hsieh MY; Chou IJ; Lim SN; Wu T; Wang HS
    Epilepsy Behav; 2018 Aug; 85():188-194. PubMed ID: 30032806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Experience With Perampanel for Refractory Pediatric Epilepsy in One Canadian Center.
    Datta AN; Xu Q; Sachedina S; Boelman C; Huh L; Connolly MB
    J Child Neurol; 2017 Aug; 32(9):834-839. PubMed ID: 28511603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years.
    Ikemoto S; Hamano SI; Hirata Y; Matsuura R; Koichihara R
    Seizure; 2019 Dec; 73():75-78. PubMed ID: 31759296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of mono- and add-on perampanel in pediatric patients with epilepsy: Experience from a single-center retrospective study.
    Li Y; Guo HL; Hu YH; Wang J; Zhang YY; Huang J; Xu J; Chen J; Lu XP; Chen F
    Epilepsia Open; 2024 Feb; 9(1):268-277. PubMed ID: 37943144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
    Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
    Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit.
    Rohracher A; Höfler J; Kalss G; Leitinger M; Kuchukhidze G; Deak I; Dobesberger J; Novak H; Pilz G; Zerbs A; Trinka E
    Epilepsy Behav; 2015 Aug; 49():354-8. PubMed ID: 25962657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: A UK and Ireland multicentre study.
    Shah E; Reuber M; Goulding P; Flynn C; Delanty N; Kemp S
    Seizure; 2016 Jan; 34():1-5. PubMed ID: 26615577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes.
    Sagar P; Wawryk O; Vogrin S; Whitham E; Kiley M; Frasca J; Carne R; Seneviratne U; Cook MJ; Lawn N; Nikpour A; D'Souza WJ
    Epilepsy Behav; 2021 Jun; 119():107935. PubMed ID: 33930626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
    Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
    Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of perampanel as an adjunct therapy in refractory epilepsy from real-world experience.
    Chang RS; Lui HKK; Leung YHI; Leung WCY; Yam KK; Wang Y
    J Neurol Sci; 2019 Oct; 405():116416. PubMed ID: 31445298
    [No Abstract]   [Full Text] [Related]  

  • 16. A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment.
    Huber B; Schmid G
    Epilepsy Behav; 2017 Jan; 66():74-79. PubMed ID: 28038390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Perampanel in treatment of refractory partial epilepsy in adolescents and adults: results of international multicenter randomized, double-blind, placebo-controlled phase III studies].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):32-8. PubMed ID: 25345628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
    Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
    Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of perampanel in patients with intellectual disability and epilepsy.
    Snoeijen-Schouwenaars FM; van Ool JS; Tan IY; Schelhaas HJ; Majoie MH
    Epilepsy Behav; 2017 Jan; 66():64-67. PubMed ID: 28038388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences.
    Biró A; Stephani U; Tarallo T; Bast T; Schlachter K; Fleger M; Kurlemann G; Fiedler B; Leiz S; Nikanorova M; Wolff M; Müller A; Selch C; Staudt M; Kluger G
    Neuropediatrics; 2015 Apr; 46(2):110-6. PubMed ID: 25730374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.